Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Haematologica. 2021 Apr 1;106(4):1182-1187. doi: 10.3324/haematol.2020.253450.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Dexamethasone / therapeutic use
  • Humans
  • Multiple Myeloma* / drug therapy
  • Neoplasm Recurrence, Local / drug therapy
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Thalidomide
  • Dexamethasone
  • pomalidomide
  • isatuximab

Associated data

  • ClinicalTrials.gov/NCT02990338

Grant support

Funding: the ICARIA-MM study was sponsored by Sanofi.